#Sweden #Stockholm #Leqembi #Nasdaq Stockholm #BioArctic AB

BioArctic AB Reports Share Issuance and Voting Power

BioArctic AB (publ), traded on Nasdaq Stockholm under the ticker BIOA B, has released significant updates regarding its share capital as of May 29, 2026. The company reported that it has issued 5,000 Class B shares during the month, which were allocated to participants involved in its stock option program that was established at the Annual General Meeting in 2019.

As of the end of May, the total shares outstanding for BioArctic AB stand at 88,724,485. These consist of two classes:

• - Class A shares: 14,399,996 (not listed)
• - Class B shares: 74,324,489 (listed)

A noteworthy feature of these shares is the voting power they confer. Each Class A share carries ten votes, whereas each Class B share is equipped with one vote. Consequently, the cumulative voting power in BioArctic is tallied at 218,324,449 votes. This elaborate structure is designed to balance the interests of different classes of shareholders while enhancing control mechanisms within the company.

This disclosure aligns with the requirements mandated by the EU Market Abuse Regulation, emphasizing BioArctic’s commitment to transparency and regulatory compliance. Such moves are crucial in maintaining shareholder trust and attracting potential investors, especially in pivotal areas like biotechnology, where investor confidence can greatly influence stock performance.

In the realm of healthcare, BioArctic AB is dedicated to pioneering innovative therapies that target neurodegenerative diseases such as Alzheimer’s. The company has gained recognition for its revolutionary medication, Leqembi® (lecanemab), which is claimed to be the first drug capable of slowing the progression of early Alzheimer's while simultaneously reducing cognitive impairments. This breakthrough therapy, developed in collaboration with Eisai, further underlines BioArctic's significant role within the biopharmaceutical landscape.

In addition to Leqembi, BioArctic’s research trajectory comprises a diverse portfolio, including antibodies aimed at treating Parkinson's disease and ALS (Amyotrophic Lateral Sclerosis). Each research initiative is bolstered by the company’s proprietary BrainTransporter™ technology, designed to help transport antibodies across the blood-brain barrier, thus increasing treatment efficacy.

BioArctic’s effort to cultivate a broad pipeline of treatments illustrates its proactive stance in the biopharmaceutical industry, working diligently towards extending the lives of countless patients across global markets. Furthermore, as the company strives for continual growth and improvement, shareholders and prospective investors alike are keenly watching its innovative trajectory and strategic developments.

The corporate transparency shown through this recent announcement reiterates BioArctic's commitment to keeping stakeholders informed about pertinent changes within the company structure. Investors wanting further insights can reach out to BioArctic's communications leads: Oskar Bosson, Vice President of Communications and Investor Relations, and Jenny Ljunggren, Manager of External Communications and Investor Relations.

In conclusion, BioArctic AB's recent activities not only signify its steady expansion and dedication to innovative treatments but also underscore the importance of shareholder engagement and compliance in a competitive market. As the company continues to develop groundbreaking therapies, it remains an attractive entity for investors interested in the biopharmaceutical sector.

For detailed investor inquiries or communication-related questions, the company encourages direct contact through their designated emails or phone numbers provided in their press release.